Individual studies suggest that Pfizer’s Paxlovid may treat COVID-19
Individual studies suggest that Pfizer’s Paxlovid may treat COVID-19

Individual studies suggest that Pfizer’s Paxlovid may treat COVID-19

Although there is research into Long COVID or Long COVID-19, whose symptoms persist for weeks and months after the first infection, there are very few ongoing clinical trials of treatments. Anecdotally, there has been what appears to be a successful treatment of Long Covid using Pfizer’s antiviral cure Paxlovid. Read on for more details.

The case of testing Pfizer’s Paxlovid for long-lasting COVID

Two cases, including one where a researcher tested Pfizer’s antiviral regimen Paxlovid on its own suggests that it would be worthwhile to run a more thorough trial to determine if the therapy would effectively treat Long COVID. Currently, Pfizer has no ongoing long COVID investigations. Although the cases are not sufficient to support taking the drug for the treatment of Long COVID, it can be seen as “hypothesis-generating” and provide a basis for testing more systematically.

Reuters notes that fewer than 20 clinical trials of Long COVID are being performed, and only five or six of them are beyond the earliest stages.

One case involved a previously healthy and vaccinated 47-year-old woman infected with COVID-19 in the summer of 2021. Most of the worst symptoms resolved within 48 hours, but severe fatigue, brain fog, post-workout fatigue, insomnia, palpitations and pain in the body continued so vigorously that she could not work. She probably became re-infected six months later and many of the acute symptoms returned. Her doctor prescribed Paxlovid. After about three days, she seemed to return to normal.

The self-reported case was Lavanya Visvabharathy, 37, an immunologist at Northwestern Medicine’s Long Covid Clinic. She was infected in December 2021 with initially mild symptoms, but chronic fatigue, headaches and sleep problems lasted for four months. She continued to test positive with signs of viral persistence. She decided to try Paxlovid. After about five days, the fatigue and insomnia improved, and after two weeks, the fatigue ceased.

A great tracking examination from Stanford University found that Long COVID could be linked to housing the virus in feces. The study showed that about half of the infected patients precipitated traces of the virus in their waste for one week after infection. Also about 4% secrete viral RNA for seven months. The RNA in the feces was also associated with stomach upset. They suspect that the virus may infect the gastrointestinal tract where it remains.

Sinovac’s Omicron-specific vaccine is launched in Hong Kong

China Sinovac Biotech Received approval to begin clinical trials in Hong Kong with its Omicron-specific vaccine. The company reported preclinical studies showing that the inactivated vaccine was safe and effective in laboratory animals. The company collected a sample of the Omicron strain in early December and “promoted active development and preclinical research.” It filed with regulators for trials in February.

Covid cases rise, admissions remain low

Although COVID-19 admissions have crawled up little, they are almost the lowest in the US as they have been for 21 months. However, there are some signs of a general increase in COVID-19 infections. Last week, Philadelphia reintroduced a mandate for the indoor mask until prices fall. USA Center for Disease Control and Prevention backed and retained mask mandates on commercial flights until at least May 3rd.

The average of seven days for new hospitalizations for COVID-19 across the United States is 1,464 compared to 1,425 the week before. In mid-January, the seven-day average exceeded 21,000. By comparison, the daily average of positive tests is 35,967, an increase of 18% from two weeks earlier. A question about the accuracy of the figure is whether positive results are reported from home tests at all. And the Johns Hopkins Coronavirus Resource Center also finds that testing generally varies significantly from region to region. For example, New Jersey tested 47 out of every 100,000 people last week, while California tested more than 1,400 out of every 100,000. It is also questionable, especially with the spring allergy season in full bloom, if people with mild symptoms such as cough and stuffy nose at all or assume it is allergy or cold.

There is proposals that we are currently in a wave similar to the one seen in March 2020 (as if to be fair looked big then but small now), but the public is tired enough and used to the rise and fall of the disease that people withdraws for further mandates.

The issue of herd immunity

Quite early in the pandemic, there were many discussion about how long it would take to achieve herd immunity, which was loosely defined as the point at which enough of the population was either vaccinated or infected for the pandemic to disappear. But the emergence of more resistant varieties threw the whole discussion in the trash until some researchers and the media picked it up and tried to redefine what herd immunity means.

Dr. Anthony Fauci, Director of National Institute of Allergy & Infectious Diseases, told CNN, “The concept of classical herd immunity may not apply to COVID-19.” And that “means we are not going to be without SARS-CoV-2 in the population for an extended period of time.”

Measles, which remains largely stable, is a case of classical herd immunity. Once you have been infected or vaccinated, you are largely protected for the rest of your life. This is not the case with COVID-19 or even other coronaviruses. Fauci pointed out that we have seen five separate variants over a two-year period, Alpha, Beta, Delta, Omicron and Omicron BA.2.

Psychiatric disorders increase the risk of COVID-19 re-infection

A study of 263,697 U.S. veterans published in JAMA network open suggests that a history of specific psychiatric disorders may increase the risk of re-infection for fully vaccinated COVID-19 survivors. Conditions included depression, post-traumatic stress disorder, anxiety, adjustment disorders, substance abuse disorders, bipolar disorder, psychosis, attention deficit hyperactivity disorder, dissociation, and eating disorders. They found that individuals with a history of these disorders had a 7% higher incidence of COVID-19 reinfection, with a 24% higher risk in patients 65 and older with substance abuse, 23% higher with psychotic disorders, 16% for bipolar disorder , and 14% for adjustment disorders and 12% for anxiety. Certain other diseases were also associated with an increased risk of re-infection: 23% for chronic kidney disease, 20% for HIV, 19% for cardiovascular disease, 17% for COPD and 13% for sleep apnea.

Selected jobs on BioSpace

Leave a Reply

Your email address will not be published.